Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

Deerfield Management bought 980,470 Celcuity shares in Q4 (estimated $80.60M trade), taking its post-trade holding to 1,714,000 shares valued at $170.95M, a quarter-end increase of $134.72M that reflects purchases and price appreciation. Celcuity’s NDA for gedatolisib was accepted with priority review and a July 17, 2026 decision date, and the stock trades at $114.37, up ~1,040% over the past year. The combination of major institutional buying and positive regulatory progress materially strengthens investor positioning and is likely to remain a significant driver of the stock.

Analysis

The concentration of a high-conviction institutional stake in a clinical-stage oncology name materially tightens available liquidity and raises the marginal cost of short exposure, amplifying short-squeeze risk ahead of binary regulatory outcomes. That structural squeeze interacts with already-elevated option implied vol, meaning dealers and market-makers will demand wider skews and larger intraday moves on news — a technical tailwind to momentum-driven rallies but a headwind to orderly de-risking by large holders.

The primary fundamental hinge remains a binary regulatory/categorical commercialization outcome followed by payer acceptance of a companion diagnostic — two distinct execution paths with different time horizons. A favorable regulatory decision can unlock multiple expansion and partnership/M&A interest within months, while any ambiguity (conditional approval, label restrictions, or reimbursement pushback) materially increases dilution risk if management needs to raise capital or partner on unfavorable economic terms.

From a sentiment and positioning angle, current positioning appears crowded and event-concentrated; that increases the odds of a violent mean reversion on a mixed readout. For investors, the optimal playbook is not a naked directional but a layered, volatility-aware approach that captures asymmetric upside to an approval/utility outcome while capping drawdowns from the sizable binary downside. Hedge ratios should treat the diagnostic commercial pathway as a second independent binary that can halve the upside even if the therapeutic clears regulatory hurdles.

Key Decisions for Investors

• Event-driven long (directional + hedged): Buy CELC Jan 2028 LEAP calls sized to 0.5% of NAV and finance ~25–33% of cost by selling 3–6 month OTM calls (diagonal/covered-call structure). Risk/reward: asymmetric—limited cash loss with >3x upside if regulatory approval + commercial uptake within 18–30 months; risk is full premium loss if negative decision.
• Volatility sell / calendar: Sell 1–3 month straddles or OTM calls to capture near-term IV and buy 9–12 month calls to retain upside through the commercialization window. Keep gross exposure small (≤0.25% NAV) due to gap risk; good if you expect post-event IV crush on clean outcome or muted moves.
• Pair trade to remove beta: Long CELC (cash or LEAPs) and short XBI (equal notional) to isolate company-specific regulatory risk from sector moves. Timeframe: 3–12 months. Risk/reward: reduces market beta; downside if sector rotates supportive while company-specific news is negative.
• Event short leg (speculative): If you prefer conviction that the move is overdone, buy deep OTM put spreads 1–3 months to capture post-event collapse risk, size ≤0.2% NAV. This contains capital at risk and benefits from gap down + IV repricing while capping loss if the event is cleanly positive.